Abstract 178P
Background
Although splenic hilar lymph node (no.10 LN) dissection did not prolong survival in proximal gastric cancer, B4-type gastric cancer remains uninvestigated for the necessity of no.10 LN dissection. This is the first study investigating the treatment effect of no.10 LN dissection in B4-type gastric cancer.
Methods
We retrospectively reviewed patients who underwent total gastrectomy for B4-type gastric cancer between 2006 and 2016 in four major institutions in Korea. Using the inverse probability of treatment weighting (IPTW) using the propensity score, the long-term survival was compared between patients with and without no.10 LN dissection.
Results
There were 540.4 patients in the no.10-dissection group and 532.69 patients in the no-dissection group in the IPTW sample. The IPTW sample showed well-balanced clinicopathological characteristics between the two groups. The no.10-dissection group showed significantly better survival than the no-dissection group (5-ysr 45.7% vs. 38.6%, p=0.036). Multivariate analysis revealed that no.10 LN dissection was an independent prognostic factor (adjusted hazard ratio [HR] = 0.747, 95% CI = 0.593 – 0.940) after adjusting for other prognostic factors.
Conclusions
No.10 LN dissection during total gastrectomy may prolong survival in B4-type gastric cancer. A large randomized controlled trial may be warranted to validate these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract